The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 20, 2012
Filed:
Jul. 23, 2007
John W. Crabb, Chagrin Falls, OH (US);
Robert G. Salomon, Mayfield Village, OH (US);
Bela Anand-apte, Shaker Heights, OH (US);
Quteba Ebrahem, Shaker Heights, OH (US);
Kutralanathan Reganathan, Cleveland, OH (US);
John W. Crabb, Chagrin Falls, OH (US);
Robert G. Salomon, Mayfield Village, OH (US);
Bela Anand-Apte, Shaker Heights, OH (US);
Quteba Ebrahem, Shaker Heights, OH (US);
Kutralanathan Reganathan, Cleveland, OH (US);
The Cleveland Clinic Foundation, Cleveland, OH (US);
Case Western Reserve University, Cleveland, OH (US);
Abstract
The present invention pertains to methods of inhibiting angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. In one embodiment, the invention is directed to methods of inhibiting ocular angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the. agent inhibits ocular angiogenesis in the individual. In another embodiment, the invention is directed to methods of inhibiting choroidal neovascularization in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the agent inhibits choroidal neovascularization in the individual.